Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03038308 · ClinicalTrials.gov registry record · Phase 1
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
A Phase 1 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03038308 is a Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 16 participants.
The verdict
NCT03038308, a Phase 1 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist ropinirole for the treatment of hyperprolactinemia in patients with idiopathic hyperprolactinemia and prolactinomas.
Interventions
- DRUG Ropinirole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-09-16 |
| Est. Completion | 2020-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03038308
The ClinicalTrials.gov registry entry for NCT03038308 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ropinirole is the first listed.
NCT03038308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03038308 about?
NCT03038308 is a clinical study titled "Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole". The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist ropinirole for the treatment of hyperprolactinemia in patients with idiopathic hyperprolactinemia and prolactinomas.
What is the current status of trial NCT03038308?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-09-16. Estimated completion is 2020-11-05.
What interventions are being tested in trial NCT03038308?
The interventions under investigation include: Ropinirole (DRUG).
Who is sponsoring clinical trial NCT03038308?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.